Aug 03, 2023 4:01 pm EDT MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
Aug 03, 2023 7:30 am EDT MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
Jul 31, 2023 8:30 am EDT MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
Jun 22, 2023 8:30 am EDT MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023 8:30 am EDT MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
Jun 09, 2023 9:00 am EDT MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
Jun 08, 2023 11:30 am EDT Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees